XNCR - ゼンコア （Xencor Inc.）

Xencor, Inc. (NASDAQ:NASDAQ:XNCR) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ETCompany ParticipantsCharles Liles - Head, Corporate Communications and IRBassil Dahiyat -…

Xencor press release (XNCR): Q4 GAAP EPS of -$0.20 beats by $0.60.Revenue of $21.6M (-86.0% Y/Y) beats by $2.36M.Cash, cash equivalents, receivables and marketable debt…

MONROVIA, Calif. (AP) — MONROVIA, Calif. (AP) — Xencor Inc. (XNCR) on Thursday reported a loss of $12 million in…

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a review of recent business and clinical highlights. “In 2022, we focused on advancing our internal portfolio of XmAb® drug candidates, including the ongoing Phase 2 studies for vudalima

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023. Xencor management will host a conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corp

Xencor (NASDAQ: XNCR ) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here''s what investors need to know before the announcement. Analysts estimate that Xencor will report an earnings per share (EPS) of $-0.68. Xencor bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and

Xencor Inc. (NASDAQ:XNCR) shares, rose in value on Friday, 08/26/22, with the stock price down by -6.01% to the previous day’s close as strong demand from buyers drove the stock to $27.85. Actively observing the price movement in the last trading, the stock closed the session at $29.63, falling within a range of $27.55 and … Is Xencor Inc. (NASDAQ: XNCR) A Good Pick For New Investors Now? Read More »

https://www.investing.com/news/pro/xencor-inc-pt-raised-to-59-at-mizuho-securities-432SI-2871042

The following slide deck was published by Xencor, Inc.

Xencor Inc. (NASDAQ:XNCR) shares, rose in value on Friday, 08/26/22, with the stock price down by -6.01% to the previous day’s close as strong demand from buyers drove the stock to $27.85. Actively observing the price movement in the last trading, the stock closed the session at $29.63, falling within a range of $27.55 and … Is Xencor Inc. (NASDAQ: XNCR) A Good Pick For New Investors Now? Read More »

https://www.investing.com/news/pro/xencor-inc-pt-raised-to-59-at-mizuho-securities-432SI-2871042

The following slide deck was published by Xencor, Inc.

Benzinga Pro data, Xencor (NASDAQ: XNCR ) reported Q2 sales of $30.18 million. Earnings fell to a loss of $33.98 million, resulting in a 244.0% decrease from last quarter. In Q1, Xencor earned $23.59 million, and total sales reached $85.50 million. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a … Full story available on Benzinga.com

Xencor (XNCR) is trading 7% lower after the company posted Q2 result that missed estimates, due to lower royalty revenues. Revenue fell 55.3% Y/Y to $30.18M, and missed estimates…